Allergoid Immunotherapy Product
Clustek is a European-developed allergoid subcutaneous immunotherapy (SCIT) product designed for safe and effective desensitisation to environmental allergens such as dust mites and grass pollens. Its chemical modification reduces allergenicity while retaining the ability to induce protective immune responses, offering a favourable safety profile for sensitive patients.
Overview
Clustek is suitable for single-allergen or multi-allergen treatment, allowing clinicians to tailor therapy to a patient’s specific sensitivities.
The product is administered exclusively in clinic by trained specialists under controlled protocols.
Safety Profile
Clustek’s allergoid formulation is associated with a lower incidence of systemic reactions compared with native extracts.
Common side effects include:
Mild local swelling or redness at the injection site
Temporary itching or discomfort
Rare systemic reactions, managed with standard emergency procedures in the clinic
Effectiveness
Clustek has demonstrated efficacy in reducing allergic symptoms and medication reliance.
Clinical response generally appears over several months, with sustained improvement expected over the recommended 3–5 year treatment course.
3–5 year treatment course
Treatment options
Single allergen therapy
Single allergen therapy:
Focuses on desensitisation to one allergen.
Multi-allergen therapy
Multi-allergen therapy:
Combines multiple allergens in one preparation, allowing treatment of patients sensitised to more than one trigger.
Both TGA-registered and non-registered options exist.
Clinics must inform patients that all options are privately funded in Australia, with total treatment costs varying from several hundred to several thousand dollars per year.
Administered via subcutaneous injection in clinic
Initial build-up phase with gradual dose increases
Maintenance phase involves less frequent injections for sustained desensitisation
Requires patient monitoring for potential adverse reactions
Patient Suitability
Clustek may be appropriate for patients who:
Have confirmed IgE-mediated allergies to environmental allergens
Are highly sensitive or at risk with native extracts
Require multi-allergen therapy options
Can commit to clinic-based SCIT protocols
Australian Context
Not PBS-subsidised; treatment is privately funded
Conclusion
Clustek provides a safe, flexible, and effective allergoid SCIT option for patients requiring desensitisation to multiple environmental allergens.
Its design balances safety with the potential for meaningful improvement in allergy symptoms over time, making it an appropriate choice for sensitive or polysensitised patients.
